{"entity":{"id":"orano-med","kind":"company","name":"Orano Med","aka":[],"tldr":"Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).","summary":"Orano Med, based in Paris and Plano, Texas, is the leading producer of lead-212 and the developer of 212Pb-DOTAMTATE, known as AlphaMedix, an alpha-emitting radioligand for somatostatin-receptor-positive neuroendocrine tumours. AlphaMedix reported a 56 percent objective response rate in its phase 2, the company builds lead-212 generators, and it works with Sanofi and RadioMedix. OnCo links it to neuroendocrine tumours, to somatostatin receptor 2 as a target, to peptide receptor radionuclide therapy, targeted alpha therapy and the isotope supply chain, and to the idea of funding alpha emitters beyond actinium-225, including lead-212, terbium-149 and astatine-211. Manufacturing cost and time for radioactive medicines is the bottleneck it sits inside. Whether lead-212 can be delivered to enough hospitals to matter is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.oranomed.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07278479"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris / Plano, TX","country":"FR","companyType":"radiopharma","website":"https://www.oranomed.com","investors":[],"funding":[]},"route":"/companies/orano-med/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"trial":[{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/"},{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"drug":[{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/"}],"company":[{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/"}],"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"idea":[{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/"},{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/"}]}}